循环miRNA-21作为急性心肌梗死的早期潜在诊断生物标志物：一项荟萃分析。
Circulating miRNA-21 as early potential diagnostic biomarker for acute myocardial infarction: a meta-analysis.
作者信息
Wang Ke, Li Kai, Li Zhuoyuan, Yan Xizhang
机构信息
Department of Clinical Medicine, Xi'an Medical University, Xi'an, Shannxi, China.
Department of the Project of Prevention and Treatment of Respiratory Diseases, Xi'an Medical University, Xi'an, Shannxi, China.
出版信息
Front Cardiovasc Med. 2024 Aug 22;11:1330884. doi: 10.3389/fcvm.2024.1330884. eCollection 2024.
INTRODUCTION
There exists a knowledge gap concerning the clinical significance of miRNA-21; therefore, in the present study, we aimed to estimate the diagnostic and prognostic accuracy and sensitivity of miRNA-21 in acute myocardial infarction (AMI) by performing an evidence-based meta-analysis of previous AMI-related clinical studies.
METHODS
Chinese and English literature published before April 2024 were searched, and data were reviewed and extracted. After quality appraisal, the STATA 16.0 software was used for the effect size analysis of the various treatments described in the literature.
RESULTS
A total of 14 valid documents were retrieved from 562 studies. The results of the systematic review revealed that for the patients with AMI vs. those without non-AMI, the aggregated odds ratio reached 5.37 (95% confidence interval 3.70-7.04). The general sensitivity and specificity for the circulating miRNA-21 levels in diagnosing AMI were 0.83 and 0.81, respectively.
DISCUSSION
Thus, the meta-analysis of 14 AMI-related clinical trials highlighted that miRNA-21 may serve as a promising biomarker for diagnosing AMI.
引言
关于miRNA - 21的临床意义存在知识空白；因此，在本研究中，我们旨在通过对先前与急性心肌梗死（AMI）相关的临床研究进行循证荟萃分析，评估miRNA - 21在急性心肌梗死中的诊断和预后准确性及敏感性。
方法
检索了2024年4月之前发表的中英文文献，并对数据进行了审查和提取。经过质量评估后，使用STATA 16.0软件对文献中描述的各种治疗方法进行效应量分析。
结果
从562项研究中总共检索到14篇有效文献。系统评价结果显示，与非AMI患者相比，AMI患者的汇总比值比达到5.37（95%置信区间3.70 - 7.04）。循环miRNA - 21水平诊断AMI的总体敏感性和特异性分别为0.83和0.81。
讨论
因此，对14项与AMI相关的临床试验进行的荟萃分析强调，miRNA - 21可能是诊断AMI的一个有前景的生物标志物。
Zotero 插件